Our top pick for
Building a portfolio
Pfenex Inc is a biotechnology business based in the US. Pfenex shares (PFNX) are listed on the NYSE MKT and all prices are listed in US Dollars. Pfenex employs 88 staff and has a trailing 12-month revenue of around USD$41.1 million.
|52-week range||USD$5.26 - USD$12.94|
|50-day moving average||USD$12.7293|
|200-day moving average||USD$9.0912|
|Wall St. target price||USD$13|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.03|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Pfenex stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pfenex's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Pfenex's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 269x. In other words, Pfenex shares trade at around 269x recent earnings.
Pfenex's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$2.6 million.
The EBITDA is a measure of a Pfenex's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$41.1 million|
|Gross profit TTM||USD$45.4 million|
|Return on assets TTM||-4.95%|
|Return on equity TTM||0%|
|Market capitalisation||USD$437.3 million|
TTM: trailing 12 months
There are currently 539,032 Pfenex shares held short by investors – that's known as Pfenex's "short interest". This figure is 31.3% down from 785,072 last month.
There are a few different ways that this level of interest in shorting Pfenex shares can be evaluated.
Pfenex's "short interest ratio" (SIR) is the quantity of Pfenex shares currently shorted divided by the average quantity of Pfenex shares traded daily (recently around 579604.30107527). Pfenex's SIR currently stands at 0.93. In other words for every 100,000 Pfenex shares traded daily on the market, roughly 930 shares are currently held short.
However Pfenex's short interest can also be evaluated against the total number of Pfenex shares, or, against the total number of tradable Pfenex shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pfenex's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Pfenex shares in existence, roughly 20 shares are currently held short) or 0.0184% of the tradable shares (for every 100,000 tradable Pfenex shares, roughly 18 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Pfenex.
Find out more about how you can short Pfenex stock.
We're not expecting Pfenex to pay a dividend over the next 12 months.
Over the last 12 months, Pfenex's shares have ranged in value from as little as $5.26 up to $12.94. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Pfenex's is 1.3233. This would suggest that Pfenex's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidate include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis. The company also develops PF743, a recombinant crisantaspase; PF745, a recombinant crisantaspase with half-life extension technology; and PF810, a peptide based next generation therapeutic which is in preclinical development, as well as offers sparX-1 (PF753) and sparX-2 (PF754). In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California. As of September 29, 2020, Pfenex Inc. operates as a subsidiary of Ligand Pharmaceuticals Incorporated.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.